-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, at an investor event held during the ASCO annual meeting, Roche gave a detailed introduction to the company's oncology R&D pipeline
.
It includes not only the Phase 3 clinical trial results of the blockbuster PD-L1 inhibitor Tecentriq as an adjuvant therapy for early non-small cell lung cancer (NSCLC) patients announced at the ASCO annual meeting, but also a number of early and late-stage research and development projects, involving The bispecific antibody platform R&D pipeline, drug development targeting the RAS signaling pathway, and the R&D layout of a new generation of immunotherapy are full of dry goods
.
Today, WuXi AppTec's content team will share the highlights of this report with readers
.